BRAF-Mutated Melanoma
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors (NCT02729298) | Sumitomo Pharma America, Inc. | 2016-12-14 |
| A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors (NCT01562899) | Pfizer | 2012-08-27 |
Track BRAF-Mutated Melanoma automatically
Every clearance here is in the API, with alerts when new ones post.